TargetMol

3-Deazauridine

Product Code:
 
TAR-T36866
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T36866-10mg10mg£102.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T36866-25mg25mg£135.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T36866-50mg50mg£173.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T36866-100mg100mg£229.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T36866-500mg500mg£485.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
3-Deazauridine is a structural analog of uridine that inhibits the biosynthesis of Cytidine-5'-Triphosphate by competitive inhibition of Cytidine Triphosphate synthetase which is considered to be the primary mode of action of this nucleoside analog.
CAS:
23205-42-7
Formula:
C10H13NO6
Molecular Weight:
243.215
Pathway:
Cell Cycle/Checkpoint; DNA Damage/DNA Repair
Purity:
0.98
SMILES:
OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(O)cc1=O
Target:
Nucleoside Antimetabolite/Analog

References

Moriconi WJ, Slavik M, Taylor S. 3-Deazauridine (NSC 126849): an interesting modulator of biochemical response. Invest New Drugs. 1986;4(1):67-84. Grant S, Cadman E. Altered 5-azacytidine metabolism following 3-deazauridine treatment of L5178Y and human myeloblasts. Cancer Res. 1980 Nov;40(11):4000-6. Raynal NJ, et al. 3-Deazauridine enhances the antileukemic action of 5-aza-2'-deoxycytidine and targets drug-resistance due to deficiency in deoxycytidine kinase. Leuk Res. 2011 Jan;35(1):110-8.